Safe and effective anti CD154 antibodies for therapeutic intervention
Safe and effective anti CD154 antibodies for therapeutic intervention
批准号:
8253027
负责人:
Susan Dana Jones
金额:
$30.0万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2012
资助国家:
美国
项目状态:
已结题
起止时间:
2012-03-01 至 2013-02-28
关键词:
AffectAlloantigenAllograft ToleranceAnimalsAntibodiesAutoimmune DiseasesAutoimmunityBindingCell TransplantationCellsClinicClinicalClinical TrialsComplementDataDevelopmentDiseaseDisease modelDisease remissionEngineeringEvaluationEventExperimental Autoimmune EncephalomyelitisFailureGoalsGovernmentGraft RejectionHumanHumoral ImmunitiesImmuneImmune responseImmunityInterventionInvestigationKnowledgeLaboratoriesLungMediatingModelingModificationMonkeysMultiple SclerosisMusMutateOrgan TransplantationOutcomePatientsPersonsPharmaceutical PreparationsPharmacologic SubstancePhasePhase II Clinical TrialsProductionProgram DevelopmentSevere Adverse EventStudy modelsSuspension substanceSuspensionsT-LymphocyteTNFSF5 geneTestingTherapeuticTherapeutic AgentsTherapeutic InterventionThrombusToxic effectTransplantationTreatment CostTreatment EfficacyVariantantibody engineeringbaseeffective therapyin vivomouse modelnonhuman primatenovelnovel therapeuticsprogramsreceptorskin allografttherapeutic target
中文摘要
描述(由申请人提供):在动物概念验证研究和初步临床试验中,有充足的数据表明CD154阻断剂在治疗自身免疫性疾病和器官移植方面具有潜在的治疗益处。然而,发展?在早期临床试验中观察到的抗体毒性阻碍了CD154作为一种治疗药物。仅在美国,就有近5000万人患有自身免疫性疾病,每年的治疗费用预计将超过1000亿美元,因此开发安全有效的治疗方法是重中之重。全世界有250万人患有多发性硬化症,其中1/5的患者在美国。目前尚不清楚是否可以消除毒性并维持疗效。CD154是一种可行且有吸引力的治疗方法,为自身免疫性疾病的治疗提供了巨大的希望。我们将把多发性硬化症作为我们的第一个临床适应症进行商业开发
英文摘要
DESCRIPTION (provided by applicant): In both animal proof of concept studies and preliminary clinical trials, there is ample data demonstrating the potential therapeutic benefits o CD154 blockade for treatment of autoimmune diseases and organ transplantation. However, development of ?CD154 as a therapeutic has been impeded by antibody toxicity observed in early clinical trials. With nearly 50 million people suffering from autoimmune diseases, in the US alone, and with treatment costs projected to be over $100B/yr, development of safe, effective therapies is an utmost priority. Worldwide 2.5 million people are affected by MS, with 1/5 of patients found in the US. It is clear if toxicity can be resolved, and efficacy sustained, ?CD154 i a viable and attractive therapeutic that offers great promise for the treatment of autoimmune diseases. We will target MS as our first clinical indication for commercial development
Existing studies strongly suggest that domains within the Fc region of the ?CD154 mAb contribute to its toxicity and therapeutic capacity. When toxicity was observed in the clinic and retrospectively in NHP, modifications were made to the antibody; while these modifications eliminated toxicity in NHP, the efficacy of ?CD154 as a tolerogenic antibody also was significantly reduced. As a result, development programs for ?CD154 as a therapeutic stalled. The goal of this proposal is to generate variant forms of the ?murine CD154 antibody that will retain the beneficial tolerogenic effects of aCD154 while greatly reducing or eliminating toxicity.
Variant forms of the antibody will be evaluated in vivo using mouse models of transplantation, cell and humoral immunity, as well as assessing their toxicity. Successful proof of concept will be the basis for creating a similar variant of the human antibody that will be developed as a novel therapeutic, which could have far-reaching impacts on the treatment of autoimmune diseases and organ transplantation.
PUBLIC HEALTH RELEVANCE: Development of aCD154 as a therapeutic for autoimmune diseases and transplantation has shown great promise in human clinical trials but development has been hindered by problems with antibody toxicity. In the past, when toxicity was reduced, the efficacy of the antibody was dramatically decreased leading to the suspension of developmental programs. This project will engineer new variants of the aCD154 antibody that will eliminate toxicity while maintaining tolerogenicity, thus allowing the potential of aCD154 to be harnessed as a novel treatment for a wide range of diseases.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
VISTA: A Novel Therapeutic Target That Negatively Regulates Immunity
-
批准号:8200942
-
项目类别:
-
资助金额:$30.0万
-
财政年份:2011
-
负责人:Susan Dana Jones
-
依托单位:
Angiogenesis antagonist plus CD40-TLR agonist adjuvant combination vaccine
-
批准号:8054408
-
项目类别:
-
资助金额:$23.75万
-
财政年份:2010
-
负责人:Susan Dana Jones
-
依托单位:
Angiogenesis antagonist plus CD40-TLR agonist adjuvant combination vaccine
-
批准号:7909550
-
项目类别:
-
资助金额:$30.0万
-
财政年份:2010
-
负责人:Susan Dana Jones
-
依托单位:
Preclinical Development of a Novel and Powerful Immunotherapeutic
-
批准号:8213450
-
项目类别:
-
资助金额:$84.76万
-
财政年份:2009
-
负责人:Susan Dana Jones
-
依托单位:
Potent Vaccine Adjuvant Therapeutic
-
批准号:7611880
-
项目类别:
-
资助金额:$30.0万
-
财政年份:2009
-
负责人:Susan Dana Jones
-
依托单位:
Preclinical Development of a Novel and Powerful Immunotherapeutic
-
批准号:8060902
-
项目类别:
-
资助金额:$92.69万
-
财政年份:2009
-
负责人:Susan Dana Jones
-
依托单位:
Preclinical Development of a Novel and Powerful Immunotherapeutic
-
批准号:8418774
-
项目类别:
-
资助金额:$86.45万
-
财政年份:2009
-
负责人:Susan Dana Jones
-
依托单位:
海外基金